JP2006527234A5 - - Google Patents

Download PDF

Info

Publication number
JP2006527234A5
JP2006527234A5 JP2006515986A JP2006515986A JP2006527234A5 JP 2006527234 A5 JP2006527234 A5 JP 2006527234A5 JP 2006515986 A JP2006515986 A JP 2006515986A JP 2006515986 A JP2006515986 A JP 2006515986A JP 2006527234 A5 JP2006527234 A5 JP 2006527234A5
Authority
JP
Japan
Prior art keywords
use according
hydroxy tamoxifen
scars
scar
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006515986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527234A (ja
JP4682129B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/006583 external-priority patent/WO2004110420A1/en
Publication of JP2006527234A publication Critical patent/JP2006527234A/ja
Publication of JP2006527234A5 publication Critical patent/JP2006527234A5/ja
Application granted granted Critical
Publication of JP4682129B2 publication Critical patent/JP4682129B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006515986A 2003-06-09 2004-06-02 4−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防 Expired - Lifetime JP4682129B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09
PCT/EP2004/006583 WO2004110420A1 (en) 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2006527234A JP2006527234A (ja) 2006-11-30
JP2006527234A5 true JP2006527234A5 (enExample) 2007-07-12
JP4682129B2 JP4682129B2 (ja) 2011-05-11

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515986A Expired - Lifetime JP4682129B2 (ja) 2003-06-09 2004-06-02 4−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防

Country Status (12)

Country Link
US (1) US7767717B2 (enExample)
EP (1) EP1631275B1 (enExample)
JP (1) JP4682129B2 (enExample)
AT (1) ATE393625T1 (enExample)
AU (1) AU2004246812B8 (enExample)
CA (1) CA2528431C (enExample)
DE (1) DE602004013439T2 (enExample)
DK (1) DK1631275T3 (enExample)
ES (1) ES2304610T3 (enExample)
NZ (1) NZ544031A (enExample)
PT (1) PT1631275E (enExample)
WO (1) WO2004110420A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1891945A1 (en) * 2006-07-31 2008-02-27 Laboratoires Besins International Treatment and prevention of excessive scarring
AU2007280440B2 (en) * 2006-07-31 2013-03-21 Besins Healthcare Luxembourg Sarl Treatment and prevention of excessive scarring
CA2710232A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CA2710388A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
CA3074440A1 (en) * 2017-09-01 2019-03-07 Excel Med, Llc Pharmaceutical composition for treating keloid and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
DE69007486T2 (de) * 1989-07-31 1994-08-11 Massachusetts Institute Of Technology, Cambridge, Mass. Verwendung von calciumantagonisten für die behandlung von narben.
TW218849B (enExample) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
DE69334068D1 (de) 1992-07-20 2006-11-16 Massachusetts Inst Technology Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
DE69813624D1 (de) * 1997-12-23 2003-05-22 Hexal Ag Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DK1317921T3 (da) * 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Similar Documents

Publication Publication Date Title
JP7145363B2 (ja) 局所皮膜形成スプレー
JP2006527234A5 (enExample)
ES2377134T3 (es) Preparación tópica de enfriamiento en forma de parche
JP2009542657A5 (enExample)
ZA200400491B (en) Treatment of nail infections with NO.
US20100292199A1 (en) Transcutaneous pharmaceutical compositions containing a steroid hormone
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
JP2001513543A (ja) 皮膚への局所適用のための非ステロイド性抗炎症薬製剤
JPH07116027B2 (ja) 経皮投与用抗炎症鎮痛剤組成物
JP4987209B2 (ja) 瘢痕形成作用を有する医薬品を製造するためのビグアニド誘導体の使用
JP2008508339A (ja) フェニトイン製剤および創傷治癒におけるその使用
JP6196704B2 (ja) 神経因性疾病の治療のための医薬
CA2528431A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
RU2007101538A (ru) Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза
US20190314325A1 (en) Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management
RU2013157834A (ru) Композиции для подкожного введения физиологически активных средств
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
CN112999199A (zh) 酮咯酸氨丁三醇凝胶贴膏的制备及应用
JPH0640947A (ja) 経皮吸収製剤用組成物および経皮吸収製剤
EA007351B1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
AU2015349153B2 (en) Application of levalbuterol formulation in treatment of skin and mucous membrane traumatic ulcers
CN115737609A (zh) 一种含草乌甲素凝胶贴膏及其制备方法
JP2764261B2 (ja) 外用消炎鎮痛剤
RU2160092C2 (ru) Антимикробный препарат для лечения инфицированных ран
CN111789832A (zh) 右酮洛芬氨丁三醇凝胶贴膏及其制备方法